The NIMH funds Delpor’s efforts to utilize its PROZORTM technology in developing a matchstick-size subcutaneous implant device capable of delivering olanzapine for 3 months through passive diffusion. The product is expected to improve medication adherence during [...]
Delpor has exclusive rights to the patented technology and has several product candidates in development, including 3-6 month formulations of exenatide, liraglutide, and basal insulin. SAN FRANCISCO, CA, April 23, 2015 – Delpor, Inc. (Delpor), [...]
The NIDDK funds Delpor’s efforts to utilize its NANOPORTM technology in developing a matchstick-size subcutaneous implant device capable of delivering exenatide for 3-12 months through passive diffusion SAN FRANCISCO, CA, Oct 14, 2014 – Delpor, Inc. (Delpor), [...]
Delpor’s innovative Prozor technology receives support from the National Institute of Mental Health in an effort to reduce relapse in patients suffering from schizophrenia and bipolar disorder. SAN FRANCISCO, CA, June 20, 2012 –Delpor, Inc. [...]
Delpor continues to strengthen its expertise in drug delivery with the addition of the former CEO of Glaxo and Alza to its Board of Directors. SAN FRANCISCO, CA, January 19, 2012 – Delpor, Inc. (Delpor), [...]
Panel of internationally renowned researchers and clinicians will guide development of Delpor’s drug delivery based products in schizophrenia, hepatitis C, diabetes, and other diseases. SAN FRANCISCO, CA, July 13, 2011 – Delpor, Inc. (Delpor), a [...]
Nanopore technology enables the sustained release of drugs during several months from a small subcutaneous implant device. SAN FRANCISCO, CA, June 23, 2011 – Delpor, Inc. (Delpor), a biotechnology company focused on drug delivery, today [...]